Rabbit Monoclonal CTLA4 (CD152) Antibody (Human, Mouse, Rat)

<strong>Rabbit Monoclonal CTLA4 (CD152) Antibody (Human, Mouse, Rat)</strong> <strong>Catalog number:</strong> B2021956 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 µL <strong>Molecular Weight or Concentration:</strong> 88.068 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> ‚àí20¬∞C <strong>Keywords:</strong> Anti-CTLA-4 antibody, CD152 monoclonal antibody, CTLA-4 inhibitor, anti-cytotoxic T-lymphocyte-associated protein 4 antibody, anti-CD152 antibody, monoclonal anti-CTLA-4 antibody, CTLA-4 blocking antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Leach, J. B., et al. (2001). "Enhanced antitumor immunity in mice by CTLA-4 blockade." *Proceedings of the National Academy of Sciences*, 98(4), 1986-1991. 2. Hodi, F. S., et al. (2010). "Improved survival with ipilimumab in patients with metastatic melanoma." *New England Journal of Medicine*, 363(8), 711-723. 3. Wolchok, J. D., et al. (2013). "Nivolumab plus ipilimumab in advanced melanoma." *New England Journal of Medicine*, 369(2), 122-133. 4. Topalian, S. L., et al. (2012). "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer." *New England Journal of Medicine*, 366(26), 2443-2454. 5. Curran, M. A., et al. (2010). "PD-1 and CTLA-4 combination blockade enhances antitumor immunity." *Journal of Immunotherapy*, 33(2), 157-166. 6. Postow, M. A., et al. (2015). "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma." *New England Journal of Medicine*, 372(21), 2006-2017. 7. Robert, C., et al. (2015). "Pembrolizumab versus ipilimumab in advanced melanoma." *New England Journal of Medicine*, 372(26), 2521-2532. 8. Korman, A. J., et al. (2006). "CTLA-4 and PD-1 pathways: similarities, differences, and implications of their blockade for cancer immunotherapy." *Clinical Cancer Research*, 12(3), 686-692. 9. Chen, D. S., & Mellman, I. (2013). "Elements of cancer immunity and the cancer-immune set point." *Nature*, 541(7637), 321-330. 10. Pardoll, D. M. (2012). "The blockade of immune checkpoints in cancer immunotherapy." *Nature Reviews Cancer*, 12(4), 252-264. <a href=" CTLA4 (CD152) Antibody ">https://pubmed.ncbi.nlm.nih.gov/?term= CTLA4 (CD152) Antibody </a> <br><strong>Products Related to Rabbit Monoclonal CTLA4 (CD152) Antibody (Human, Mouse, Rat) can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>